Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 95,823 | 120,122 | 20,943 | 37,354 | 56,221 |
| Marketable Securities | 41,966 | 28,114 | 27,174 | 28,514 | 44,556 |
| Receivables | 15,443 | 12,847 | 15,505 | 12,493 | 12,704 |
| Inventories | 5,673 | 5,002 | 4,988 | 5,466 | 4,325 |
| TOTAL | $169,186 | $182,123 | $81,333 | $95,973 | $128,907 |
| Non-Current Assets | |||||
| PPE Net | 689 | 823 | 910 | 1,103 | 1,297 |
| Investments And Advances | 4,502 | 6,507 | 7,970 | 10,165 | 0 |
| Other Non-Current Assets | 3,934 | 4,180 | 5,148 | 5,713 | 5,415 |
| TOTAL | $9,125 | $11,510 | $14,028 | $16,981 | $6,712 |
| Total Assets | $178,311 | $193,633 | $95,361 | $112,954 | $135,619 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 16,538 | 14,083 | 16,403 | 17,130 | 12,383 |
| Accrued Expenses | 10,814 | 8,152 | 6,721 | 4,919 | 8,257 |
| Other current liabilities | 3,860 | 3,553 | 3,641 | 3,185 | 3,276 |
| TOTAL | $31,212 | $25,788 | $26,765 | $25,234 | $23,916 |
| Non-Current Liabilities | |||||
| Long Term Debt | 98,551 | 98,518 | 98,296 | 97,941 | 97,537 |
| Other Non-Current Liabilities | 113,760 | 111,320 | 108,734 | 106,333 | 103,527 |
| TOTAL | $212,311 | $209,838 | $207,030 | $204,274 | $201,064 |
| Total Liabilities | $243,523 | $235,626 | $233,795 | $229,508 | $224,980 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 34,122 | 30,866 | 30,283 | 23,454 | 23,441 |
| Common Shares | 89 | 84 | 64 | 64 | 63 |
| Retained earnings | -679,348 | -653,332 | -631,453 | -607,317 | -577,104 |
| Other shareholders' equity | 12 | -134 | -154 | -45 | -107 |
| TOTAL | $-65,212 | $-41,993 | $-138,434 | $-116,554 | $-89,361 |
| Total Liabilities And Equity | $178,311 | $193,633 | $95,361 | $112,954 | $135,619 |